Continuous therapy response references for BCR::ABL1 monitoring in pediatric chronic myeloid leukemia

Response to tyrosine kinase inhibitor (TKI) therapy in patients with chronic myeloid leukemia (CML) is monitored by quantification of BCR::ABL1 transcript levels. Milestones for assessing optimal treatment response have been defined in adult CML patients and are applied to children and adolescents a...

Descripción completa

Detalles Bibliográficos
Autores principales: Volz, Christian, Zerjatke, Thomas, Gottschalk, Andrea, Semper, Sabine, Suttorp, Meinolf, Glauche, Ingmar, Krumbholz, Manuela, Metzler, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598002/
https://www.ncbi.nlm.nih.gov/pubmed/37875583
http://dx.doi.org/10.1038/s41598-023-45364-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10598002/
https://www.ncbi.nlm.nih.gov/pubmed/37875583
http://dx.doi.org/10.1038/s41598-023-45364-0

Ejemplares similares